Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ONCR 177

Next Previous
Drug Profile

ONCR 177

Alternative Names: ONCR-177

Latest Information Update: 01 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oncorus
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action CCL4 protein expression stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Fms-like tyrosine kinase 3 expression stimulants; Interleukin-12 expression stimulants; Programmed cell death 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 13 Sep 2024 Efficacy and adverse events data from the phase I trial in Solid tumours was presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 31 May 2023 Oncorus terminates a phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Combination therapy) in Canada and USA (Intratumoural), dure to portfolio reprioritization (NCT04348916)
  • 31 May 2023 Oncorus terminates a phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in Canada and USA (Intratumoural), dure to portfolio reprioritization (NCT04348916)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top